365 related articles for article (PubMed ID: 28178969)
1. Neuroblastoma treatment in the post-genomic era.
Esposito MR; Aveic S; Seydel A; Tonini GP
J Biomed Sci; 2017 Feb; 24(1):14. PubMed ID: 28178969
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy for Neuroblastoma: ALK Inhibitors.
Schulte JH; Schulte S; Heukamp LC; Astrahantseff K; Stephan H; Fischer M; Schramm A; Eggert A
Klin Padiatr; 2013 Nov; 225(6):303-8. PubMed ID: 24166094
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms and therapeutic targets in neuroblastoma.
Johnsen JI; Dyberg C; Fransson S; Wickström M
Pharmacol Res; 2018 May; 131():164-176. PubMed ID: 29466695
[TBL] [Abstract][Full Text] [Related]
5. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
Toyokawa G; Seto T
Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
7. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f.
Harvey H; Piskareva O; Creevey L; Alcock LC; Buckley PG; O'Sullivan MJ; Segura MF; Gallego S; Stallings RL; Bray IM
Int J Cancer; 2015 Apr; 136(7):1579-88. PubMed ID: 25137037
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.
Krytska K; Ryles HT; Sano R; Raman P; Infarinato NR; Hansel TD; Makena MR; Song MM; Reynolds CP; Mossé YP
Clin Cancer Res; 2016 Feb; 22(4):948-60. PubMed ID: 26438783
[TBL] [Abstract][Full Text] [Related]
9. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
Perez CA; Velez M; Raez LE; Santos ES
Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
[TBL] [Abstract][Full Text] [Related]
11. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro.
Piskareva O; Harvey H; Nolan J; Conlon R; Alcock L; Buckley P; Dowling P; Henry M; O'Sullivan F; Bray I; Stallings RL
Cancer Lett; 2015 Aug; 364(2):142-55. PubMed ID: 25960282
[TBL] [Abstract][Full Text] [Related]
12. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.
Amoroso L; Haupt R; Garaventa A; Ponzoni M
Expert Opin Investig Drugs; 2017 Nov; 26(11):1281-1293. PubMed ID: 28906153
[TBL] [Abstract][Full Text] [Related]
13. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
14. The mTOR signaling pathway in pediatric neuroblastoma.
Mei H; Wang Y; Lin Z; Tong Q
Pediatr Hematol Oncol; 2013 Oct; 30(7):605-15. PubMed ID: 23697980
[TBL] [Abstract][Full Text] [Related]
15. Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas.
Yan B; Lim M; Zhou L; Kuick CH; Leong MY; Yong KJ; Aung L; Salto-Tellez M; Chang KT
J Clin Pathol; 2013 Nov; 66(11):985-91. PubMed ID: 23801497
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
18. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
19. Treatment of ALK-positive non-small cell lung cancer.
Bang YJ
Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
[TBL] [Abstract][Full Text] [Related]
20. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]